1. $Eli Lilly(LLY)$ soared to a record high of $613 on October 12th.
Eli Lilly and Novo Nordisk announced that it plans to stop a kidney outcomes clinical trial evaluating Ozempic (semaglutide) in treating patients with type 2 diabetes and chronic kidney disease.
The study’s independent data monitoring committee recommended the trial be halted because results from an interim analysis showed an efficacy level that met pre-specified criteria.
Lilly is also evaluating Mounjaro in a phase 2 study targeting chronic kidney disease.
2. $Aflac(AFL)$ climbed to $80.50 on October 12th.
Aflac is a supplemental health and life insurance provider in the US and Japan. The company has been expanding its product offerings to include accidents, disability, and long-term-care insurance.
Over the past year the S&P 500 is higher by 20.51% while AFL has gained 36.37%. AFL earned $7.47 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 10.6.
3. $Ares Management LP(ARES)$ achieved a record high of $112.15 on October 12th.
Ares Management has launched the Ares European Strategic Income Fund, an open-ended direct lending fund.
This initiative provides individual investors in Europe and Asia with access to Ares's European direct lending strategy, enhancing their investment opportunities in the region.
4. $Cadence Design(CDNS)$ reached $255.85 on October 12th.
Shares of the maker of hardware and software products for validating chip designs witnessed a gain of 5.62% over the previous month, beating the performance of the Computer and Technology sector with its loss of 1.56%.
5. $McKesson(MCK)$ traded at $461.32 on October 12th.
McKesson, drug distributor, received a target price of $485.00 to $490.00 from Evercore ISI analysts.
6. $Synopsys(SNPS)$ reached a substantial value of $502.66 on October 12th.
Synopsys, the semiconductor company, consistently demonstrated robust financials, boasting a net margin of 18.71% and a return on equity of 18.01%.
Comments
Great ariticle, would you like to share it?
Great ariticle, would you like to share it?
Great ariticle, would you like to share it?
Great ariticle, would you like to share it?